UK markets closed

Y-mAbs Therapeutics, Inc. (YMAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.98-0.02 (-0.13%)
As of 03:23PM EDT. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
84,819
84,819
65,267
34,897
20,750
Cost of revenue
11,416
11,416
7,567
2,514
2,203
Gross profit
73,403
73,403
57,700
32,383
18,547
Operating expenses
Research development
54,219
54,219
91,572
93,245
93,697
Selling general and administrative
44,856
44,856
60,939
54,571
44,785
Total operating expenses
99,075
99,075
152,511
147,816
138,482
Operating income or loss
-25,672
-25,672
-94,811
-115,433
-119,935
Interest expense
-
-
757
1,852
-
Total other income/expenses net
-
-
-
62,010
-
Income before tax
-20,866
-20,866
-95,568
-55,275
-119,337
Income tax expense
561
561
0
-
-
Income from continuing operations
-21,427
-21,427
-95,568
-55,275
-119,337
Net income
-21,427
-21,427
-95,568
-55,275
-119,337
Net income available to common shareholders
-21,427
-21,427
-95,568
-55,275
-119,337
Basic EPS
-0.45
-
-2.19
-1.28
-2.97
Diluted EPS
-0.45
-
-2.19
-1.28
-2.97
Basic average shares
43,656
-
43,704
43,182
40,119
Diluted average shares
43,656
-
43,704
43,182
40,119